PYFA.JK(PYFA.JK)
PYFA.JK
PT Pyridam Farma Tbk is a leading Indonesian pharmaceutical company specializing in the production of generic and specialty drugs, with a significant market presence in Southeast Asia. The company differentiates itself through its extensive product portfolio and strategic partnerships, particularly in the oncology and cardiovascular segments.
Pyridam generates revenue primarily through the sale of generic pharmaceuticals, which benefit from lower production costs and high volume sales. The company leverages its established distribution network across Indonesia and neighboring countries to maintain pricing power and competitive advantages in a fragmented market.
Regulatory approvals for new drug formulations
Market share changes in the generic drug segment
Partnership developments with international pharmaceutical firms
Pricing pressures from government healthcare policies
Regulatory changes impacting drug pricing and approval processes
Technological disruption in drug manufacturing processes
Increasing competition from local and international generic manufacturers
Potential entry of large multinational pharmaceutical companies into the Indonesian market
High debt levels (Debt/Equity of 7.03) may limit financial flexibility
Negative operating cash flow could affect liquidity
moderate - As a healthcare provider, Pyridam's performance is somewhat insulated from economic downturns; however, reduced consumer spending can impact sales of over-the-counter products.
Rising interest rates may increase financing costs for Pyridam, affecting its ability to invest in R&D and expansion, which could pressure margins and valuation multiples.
minimal - The company does not heavily rely on credit markets for operations, but high debt levels could pose risks if credit conditions tighten.
growth - Investors may be drawn to Pyridam for its potential in the expanding Southeast Asian pharmaceutical market.
high - The stock has exhibited significant price volatility, as evidenced by a 61.4% decline over the past six months.